Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationships Between Bronchodilator Reversibility and Mannitol Airway Hyperresponsiveness in Severe Asthma.

Clinical and translational allergy·2026
Same author

Impact of dupilumab on Sino-Nasal Outcome Test-22 (SNOT-22) domains: Focus on the ear.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Impact of dupilumab on united airways disease.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Are Phenotypic Baseline Characteristics Related to Abolition of AHR After Benralizumab and Dupilumab?

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Bucher indirect treatment comparison of phase 3 trials with dupilumab and tezepelumab in chronic rhinosinusitis with nasal polyps.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Revisiting Type 2 Inflammation and Airway Hyper-responsiveness in COPD.

The journal of allergy and clinical immunology. In practice·2026

Related Experiment Video

Updated: Jun 19, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Think the impossible: beta-blockers for treating asthma.

Brian J Lipworth1, Peter A Williamson

  • 1Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee DD3 0QW, Scotland, UK. brianlipworth@gmail.com

Clinical Science (London, England : 1979)
|October 8, 2009
PubMed
Summary

Beta-blockers may worsen asthma acutely but could offer benefits with chronic use. This research explores their potential to reduce airway hyperresponsiveness in asthma patients.

More Related Videos

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

Related Experiment Videos

Last Updated: Jun 19, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Immunology

Background:

  • Asthma is often linked to impaired beta2-adrenoceptor (beta2ADR) function, favoring parasympathetic bronchoconstriction.
  • Beta-blocking drugs can induce acute bronchoconstriction, potentially mitigated by anticholinergic agents.
  • Chronic beta2-agonist use leads to reduced beta2ADR and desensitization, increasing asthma exacerbations.

Purpose of the Study:

  • To investigate the hypothesis that chronic beta-blocker administration may attenuate airway hyperresponsiveness in asthma.
  • To explore potential beneficial effects of long-term beta-blocker use, contrasting with acute effects.

Main Methods:

  • The study examines the effects of beta-blocker dosing on airway responsiveness.
  • Specific methodologies likely involve in vivo or in vitro models assessing beta2ADR function and airway constriction.

Main Results:

  • Single-dose beta-blocker administration is associated with acute bronchoconstriction.
  • Chronic beta-blocker dosing may lead to beneficial effects, including reduced airway hyperresponsiveness.

Conclusions:

  • While acute beta-blocker use can be detrimental in asthma, chronic administration presents a potential therapeutic avenue.
  • Further research is warranted to explore the long-term benefits of beta-blockers in managing airway hyperresponsiveness.